Skip to content

Investigating the effect of Citrus aurantium blossom capsule on the symptoms of patients with major depressive disorder

Investigating the effect of Citrus aurantium blossom capsule on the symptoms of patients with major depressive disorder (MDD), a double-blind placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250527065932N1
Enrollment
50
Registered
2025-09-28
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder. Major depressive disorder, single episode, moderate

Interventions

Intervention 1: The intervention group receives capsules containing dried orange blossom (500 mg, twice daily) along with standard antidepressant treatment. Intervention 2: The control group receives

Sponsors

Fasa University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Having major depressive disorder as diagnosed by a specialist physician and based on the DMS-5 criteria Having moderate to severe depression (BDI score greater than or equal to 18) Willingness and consent to participate in the research project (by completing and signing the informed consent form)

Exclusion criteria

Exclusion criteria: Recent use of medications that interact with bergamot, such as SSRIs or MAO inhibitors Recent use of herbal medicines with psychoactive effects History of bipolar disorder or psychosis Substance abuse 6 months before the start of the study Allergies to medicinal plants such as hives, itchy skin, nausea, vomiting, stomach cramps, and stomach pain Becoming pregnant during the study or planning to become pregnant during the study Having chronic diseases such as diabetes, high blood pressure Liver disease and malignant diseases

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: 0-4-8 weeks. Method of measurement: questionnaire.;DMS-5. Timepoint: 0-4-8 weeks. Method of measurement: Beck Questionar.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarokh Baharluie

Fasa University of Medical Sciences

ahmad.baharloui1348@gmail.com+98 71 5335 0994

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026